Merck & Co., Inc.

The forensic data available here is limited. The Beneish M-Score, Altman Z-Score, Piotroski F-Score, and Fog Index are not on file for this filing, so no values are given for them. The two computed measures are operating cash flow divided by net income, which is 1.25 for 2024-FY, meaning operating cash flow of $21.47 billion was about 1.25 times net income of $17.12 billion. In plain terms, reported profit was backed by cash generated from operations in that year. The ratio is a single-year snapshot, though, and 2023 operating cash flow of $13.01 billion against net income of $365 million shows how volatile the relationship can be. Revenue growth of 6.7% for 2024-FY is a simple year-over-year change from $64.17 billion to $60.12 billion in 2023. Against that, the MD&A's 2025 figures show growth slowing to 1%. Several pipeline items cited in the excerpt, including the FDA review of doravirine/islatravir, the priority review of Welireg with Keytruda for adjuvant renal cell carcinoma, the Winrevair label update under review based on the HYPERION trial, and the Cidara acquisition that closed in January 2026, are described as future or recent steps rather than proven sales contributors. Readers may want to look at the MD&A's segment discussion and the reconciliation of GAAP to non-GAAP results, since that is where the gap between the narrative and reported earnings is easiest to trace. The filing excerpt is truncated, so later sections, including any full risk factors, were not available for this review.

Catalyst.According to the MD&A, worldwide sales were $65.0 billion in 2025, up 1% from 2024 (2% excluding unfavorable foreign exchange). The company attributes growth mainly to oncology, cardiometabolic and respiratory, diabetes, and animal health, offset by declines in vaccines, immunology (after marketing rights ended in 2024), and virology, driven largely by lower sales of Lagevrio. Recent drivers named include the Keytruda Qlex launch, the expanded U.S. indication for Winrevair, the Enflonsia launch, and the Verona Pharma acquisition, which brought in Ohtuvayre for COPD. GAAP net income attributable to Merck was $18.25 billion in 2025, up 7% from $17.12 billion in 2024.

Hidden risk.The most material tension is in earnings consistency and leverage rather than headline sales. GAAP net income fell from $14.52 billion in 2022 to $365 million in 2023, then recovered to $17.12 billion in 2024, so single-year comparisons can mislead. The 2025 MD&A shows non-GAAP net income of $22.51 billion against GAAP net income of $18.25 billion, a gap of about $4.26 billion from acquisition, divestiture, restructuring, and other items the company excludes. Long-term debt rose from $21.35 billion in 2017 to $34.46 billion in 2024, and equity fell from $45.99 billion in 2022 to $37.58 billion in 2023. No risk-factor text is on file for this review, so these points rest on the financial statements and MD&A.